STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMLX
  4. [Form 4] Amylyx Pharmaceuticals, Inc. Insider Trading Activity

Amylyx Pharmaceuticals (AMLX) Co-CEO Cohen sells shares after option exercises

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported option exercises and related share sales. On January 15, 2026, he exercised 197,182 stock options at $7.57 per share and sold 136,193 shares of common stock at a weighted average price of $13.5895. On January 16, 2026, he exercised an additional 2,818 stock options at $7.57 per share and sold 1,974 shares at a weighted average price of $13.8293. A footnote states that shares were sold to cover option cost and tax obligations under a preset sales plan adopted on November 12, 2025. After these transactions, Cohen directly beneficially owned 3,379,465 shares of Amylyx common stock.

Positive

  • None.

Negative

  • None.
Insider Cohen Joshua B
Role Co-Chief Executive Officer
Sold 138,167 shs ($1.88M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 2,818 $0.00 --
Exercise Common Stock 2,818 $7.57 $21K
Sale Common Stock 1,974 $13.8293 $27K
Exercise Stock Option (Right to Buy) 197,182 $0.00 --
Exercise Common Stock 197,182 $7.57 $1.49M
Sale Common Stock 136,193 $13.5895 $1.85M
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 3,381,439 shares (Direct)
Footnotes (1)
  1. Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.82 to $13.835. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. This option is fully vested and exercisable. The option is due to expire on February 19, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cohen Joshua B
(Last) (First) (Middle)
C/O AMYLYX PHARMACEUTICALS, INC.
55 CAMBRIDGE PARKWAY, SUITE 6W
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Co-Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/15/2026 M 197,182 A $7.57 3,514,814 D
Common Stock 01/15/2026 S(1) 136,193 D $13.5895(2) 3,378,621 D
Common Stock 01/16/2026 M 2,818 A $7.57 3,381,439 D
Common Stock 01/16/2026 S(1) 1,974 D $13.8293(3) 3,379,465 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $7.57 01/15/2026 M 197,182 (4) 02/19/2026 Common Stock 197,182 $0 2,818 D
Stock Option (Right to Buy) $7.57 01/16/2026 M 2,818 (4) 02/19/2026 Common Stock 2,818 $0 0 D
Explanation of Responses:
1. Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.82 to $13.835. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
4. This option is fully vested and exercisable. The option is due to expire on February 19, 2026.
/s/ Joshua B. Cohen 01/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Amylyx (AMLX) Co-CEO Joshua B. Cohen report?

Joshua B. Cohen, Co-Chief Executive Officer and director of Amylyx Pharmaceuticals, Inc., reported exercising stock options and selling common shares on January 15, 2026 and January 16, 2026. The filing shows both the option exercises at $7.57 per share and related sales of Amylyx common stock.

How many Amylyx stock options did Joshua B. Cohen exercise in this Form 4?

The Form 4 reports that Cohen exercised 197,182 stock options on January 15, 2026 at an exercise price of $7.57 per share and 2,818 stock options on January 16, 2026 at the same exercise price.

How many Amylyx (AMLX) shares did Joshua B. Cohen sell and at what prices?

Cohen sold 136,193 shares of Amylyx common stock on January 15, 2026 at a weighted average price of $13.5895 per share and 1,974 shares on January 16, 2026 at a weighted average price of $13.8293 per share. Footnotes explain that each reported price is a weighted average for multiple trades within disclosed price ranges.

Why did Amylyx Co-CEO Joshua B. Cohen sell shares in this filing?

A footnote states that the reported share sales reflect shares sold to cover option cost and tax obligations upon the option exercises. These sales were made pursuant to a preset sales plan adopted by Cohen on November 12, 2025.

How many Amylyx shares does Joshua B. Cohen own after these transactions?

Following the reported transactions on January 15–16, 2026, Cohen directly beneficially owned 3,379,465 shares of Amylyx Pharmaceuticals, Inc. common stock, as shown in Table I of the filing.

What is the status of the stock options involved in Joshua B. Cohen’s Form 4?

A footnote explains that the reported stock option is fully vested and exercisable and is due to expire on February 19, 2026. The options had an exercise price of $7.57 per share.

What roles does Joshua B. Cohen hold at Amylyx Pharmaceuticals (AMLX)?

The Form 4 identifies Joshua B. Cohen as both a director and an officer of Amylyx Pharmaceuticals, Inc., with the officer title of Co-Chief Executive Officer. He is not listed as a 10% owner in this filing.